Related Experiment Video
Updated: Jan 18, 2026
08:46
A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma DIPG
Published on: March 7, 2017
17.5K
Radiotherapy plus neoadjuvant and concomitant IL-13Rα2-directed immunotoxin therapy for diffuse intrinsic pontine
Julian S Rechberger1,2, Wouter J F Vanbilloen1,3, Leo F Nonnenbroich4,5
1Department of Neurologic Surgery, Mayo Clinic, Rochester, MN, USA.
Communications Biology
|January 16, 2026
Summary
Radiotherapy combined with the IL-13Rα2-targeted immunotoxin GB13 shows promise for treating diffuse intrinsic pontine glioma (DIPG). This combination therapy enhances radiotherapy
Area of Science:
- Oncology
- Immunotherapy
- Radiotherapy
Background:
- Diffuse intrinsic pontine glioma (DIPG) is a pediatric brain tumor with limited treatment options.
- Radiotherapy (RT) is palliative for DIPG.
- Interleukin 13 receptor subunit alpha 2 (IL-13Rα2) is a promising therapeutic target in DIPG.
Purpose of the Study:
- To evaluate the efficacy of combining RT with an IL-13Rα2-targeted immunotoxin (GB13) for DIPG treatment.
- To assess the safety and tolerability of this combined approach.
Main Methods:
- In vitro studies using DIPG cell lines and in vivo studies using DIPG mouse models.
- Comparison of RT alone versus RT plus GB13.
- Evaluation of DNA damage, apoptosis, cell viability, proliferation, tumor burden, and survival.
Main Results:
- GB13 enhanced RT efficacy in vitro by inhibiting DNA damage repair and modulating apoptotic signaling.
- Combined RT and GB13 treatment decreased tumor burden and prolonged survival in mouse models.
- The combination therapy was well tolerated.
Conclusions:
- RT plus GB13 is a safe and effective therapeutic strategy for DIPG.
- This combination warrants further investigation as a novel treatment approach for DIPG.
